Literature DB >> 12183225

N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity.

Corinne J Hackbarth1, Dawn Z Chen, Jason G Lewis, Kirk Clark, James B Mangold, Jeffrey A Cramer, Peter S Margolis, Wen Wang, Jim Koehn, Charlotte Wu, S Lopez, George Withers, Helen Gu, Elina Dunn, R Kulathila, Shi-Hao Pan, Wilma L Porter, Jeff Jacobs, Joaquim Trias, Dinesh V Patel, Beat Weidmann, Richard J White, Zhengyu Yuan.   

Abstract

Peptide deformylase (PDF) is a prokaryotic metalloenzyme that is essential for bacterial growth and is a new target for the development of antibacterial agents. All previously reported PDF inhibitors with sufficient antibacterial activity share the structural feature of a 2-substituted alkanoyl at the P(1)' site. Using a combination of iterative parallel synthesis and traditional medicinal chemistry, we have identified a new class of PDF inhibitors with N-alkyl urea at the P(1)' site. Compounds with MICs of <or=4 micro g/ml against gram-positive and gram-negative pathogens, including Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae, have been identified. The concentrations needed to inhibit 50% of enzyme activity (IC(50)s) for Escherichia coli Ni-PDF were <or=0.1 micro M, demonstrating the specificity of the inhibitors. In addition, these compounds were very selective for PDF, with IC(50)s of consistently >200 micro M for matrilysin and other mammalian metalloproteases. Structure-activity relationship analysis identified preferred substitutions resulting in improved potency and decreased cytotoxity. One of the compounds (VRC4307) was cocrystallized with PDF, and the enzyme-inhibitor structure was determined at a resolution of 1.7 A. This structural information indicated that the urea compounds adopt a binding position similar to that previously determined for succinate hydroxamates. Two compounds, VRC4232 and VRC4307, displayed in vivo efficacy in a mouse protection assay, with 50% protective doses of 30.8 and 17.9 mg/kg of body weight, respectively. These N-alkyl urea hydroxamic acids provide a starting point for identifying new PDF inhibitors that can serve as antimicrobial agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183225      PMCID: PMC127453          DOI: 10.1128/AAC.46.9.2752-2764.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

Review 1.  Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents.

Authors:  C Giglione; M Pierre; T Meinnel
Journal:  Mol Microbiol       Date:  2000-06       Impact factor: 3.501

Review 2.  Inhibitors of protein synthesis.

Authors:  I Leviton
Journal:  Cancer Invest       Date:  1999       Impact factor: 2.176

3.  Global transposon mutagenesis and a minimal Mycoplasma genome.

Authors:  C A Hutchison; S N Peterson; S R Gill; R T Cline; O White; C M Fraser; H O Smith; J C Venter
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

4.  Crystal structure of the Escherichia coli peptide deformylase.

Authors:  M K Chan; W Gong; P T Rajagopalan; B Hao; C M Tsai; D Pei
Journal:  Biochemistry       Date:  1997-11-11       Impact factor: 3.162

5.  Synthesis and antibacterial activity of peptide deformylase inhibitors.

Authors:  K M Huntington; T Yi; Y Wei; D Pei
Journal:  Biochemistry       Date:  2000-04-18       Impact factor: 3.162

6.  A new subclass of the zinc metalloproteases superfamily revealed by the solution structure of peptide deformylase.

Authors:  T Meinnel; S Blanquet; F Dardel
Journal:  J Mol Biol       Date:  1996-09-27       Impact factor: 5.469

7.  Spectrophotometric assay for vertebrate collagenase.

Authors:  H Weingarten; J Feder
Journal:  Anal Biochem       Date:  1985-06       Impact factor: 3.365

8.  Control of peptide deformylase activity by metal cations.

Authors:  S Ragusa; S Blanquet; T Meinnel
Journal:  J Mol Biol       Date:  1998-07-17       Impact factor: 5.469

9.  Mapping of the active site zinc ligands of peptide deformylase.

Authors:  T Meinnel; C Lazennec; S Blanquet
Journal:  J Mol Biol       Date:  1995-11-24       Impact factor: 5.469

10.  Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation.

Authors:  D Mazel; S Pochet; P Marlière
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more
  21 in total

1.  Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor.

Authors:  Sandhya Ramanathan-Girish; Juliet McColm; John M Clements; Phil Taupin; Sue Barrowcliffe; John Hevizi; Sharon Safrin; Clive Moore; Gary Patou; Heinz Moser; Alison Gadd; Ute Hoch; Vernon Jiang; Denene Lofland; Kirk W Johnson
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Mutations in three distinct loci cause resistance to peptide deformylase inhibitors in Bacillus subtilis.

Authors:  Yann Duroc; Carmela Giglione; Thierry Meinnel
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

Review 3.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Insights from ligand and structure based methods in virtual screening of selective Ni-peptide deformylase inhibitors.

Authors:  Ravi Shekar Ananthula; Muttineni Ravikumar; S K Mahmood; M N S Pavan Kumar
Journal:  J Mol Model       Date:  2011-05-12       Impact factor: 1.810

5.  URD12: A urea derivative with marked antitumor activities.

Authors:  Ai-Yun Wang; Yin Lu; Hai-Liang Zhu; Qing-Cai Jiao
Journal:  Oncol Lett       Date:  2011-11-08       Impact factor: 2.967

6.  Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.

Authors:  Thomas R Fritsche; Helio S Sader; Roy Cleeland; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics.

Authors:  Mona D Lee; Yuhong She; Michael J Soskis; Christopher P Borella; Jeffrey R Gardner; Paula A Hayes; Benzon M Dy; Mark L Heaney; Mark R Philips; William G Bornmann; Francis M Sirotnak; David A Scheinberg
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

8.  The Search for Herbal Antibiotics: An In-Silico Investigation of Antibacterial Phytochemicals.

Authors:  Mary Snow Setzer; Javad Sharifi-Rad; William N Setzer
Journal:  Antibiotics (Basel)       Date:  2016-09-12

9.  Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression.

Authors:  Ruth E Caughlan; Shubha Sriram; Denis M Daigle; Angela L Woods; Jennifer Buco; Ron L Peterson; Joann Dzink-Fox; Susan Walker; Charles R Dean
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

10.  Subinhibitory concentrations of the deformylase inhibitor actinonin increase bacterial release of neutrophil-activating peptides: a new approach to antimicrobial chemotherapy.

Authors:  Huamei Fu; Claes Dahlgren; Johan Bylund
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.